Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
42

Recommended

Sales growth but lack of margin expansion due to competition.

Johannes Faul, CFA | 15 June 2026

Discounted Aussie shares that offer a tax rebate.

Tyger Fitzpatrick | 14 June 2026

Pre-IPO holders could start selling later this summer, and earnings will be an important test.

Tom Lauricella | 14 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,128.00	14.60	0.16%
CAC 40	8,435.26	84.39	1.01%
DAX 40	24,921.35	286.05	1.16%
Dow JONES (US)	51,202.26	353.51	0.70%
FTSE 100	10,485.06	13.34	0.13%
HKSE	24,842.67	124.57	0.50%
NASDAQ	25,888.84	79.18	0.31%
Nikkei 225	69,317.50	3,297.46	4.99%
NZX 50 Index	13,360.59	33.28	-0.25%
S&P 500	7,431.46	37.16	0.50%
S&P/ASX 200	8,914.00	7.00	0.08%
SSE Composite Index	4,096.47	64.96	1.61%